source
- Eli Lilly to acquire Merida Biosciences for up to $2.875 billion, bolstering its immunology pipelineEli Lilly announced a deal to purchase Merida Biosciences, a biotech focused on immunology, for a total consideration that could reach $2.875 billion. The acquisition adds Merida's assets in fast-…
- Cytokinetics reports Phase 3 success for Myqorzo but shares tumble as investors weigh market impactAt the European Society of Cardiology meeting, Cytokinetics presented Phase 3 data for Myqorzo in non‑obstructive hypertrophic cardiomyopathy, showing benefit in both forms of the disease and disti…